Advertisements

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®.....»»

Category: press-releasesSource: businesswireindiaJun 14th, 2017

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®.....»»

Category: press-releasesSource: businesswireindiaJul 28th, 2017

Cyltezo®, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of multiple chronic inflammatory diseases

Cyltezo®, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of multiple chronic inflammatory diseases.....»»

Category: press-releasesSource: businesswireindiaNov 13th, 2017

Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®

Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®.....»»

Category: press-releasesSource: businesswireindiaSep 16th, 2017

Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH

Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH.....»»

Category: press-releasesSource: businesswireindiaAug 24th, 2017

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations.....»»

Category: press-releasesSource: businesswireindiaJul 12th, 2017

Lupin JV announces outcome of Phase III study for biosimilar, Etanercept

Lupin JV announces outcome of Phase III study for biosimilar, Etanercept.....»»

Category: topSource: moneycontrolFeb 7th, 2018

Lupin JV announces outcome of Phase III study for biosimilar, Etanercept

Lupin JV announces outcome of Phase III study for biosimilar, Etanercept.....»»

Category: topSource: moneycontrolFeb 7th, 2018

Glenmark Pharma presents preliminary biomarker data on GBR 1302

Glenmark Pharma presents preliminary biomarker data on GBR 1302.....»»

Category: topSource: moneycontrolJan 24th, 2018

Glenmark Pharma announces results from phase 3 safety study evaluating Ryaltris

Glenmark Pharma announces results from phase 3 safety study evaluating Ryaltris.....»»

Category: topSource: moneycontrolDec 13th, 2017

Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy

Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy.....»»

Category: press-releasesSource: businesswireindiaNov 16th, 2017

Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIG™ (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer

Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIG™ (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer.....»»

Category: press-releasesSource: businesswireindiaOct 16th, 2017

Glenmark’s dermatitis molecule displays positive results in phase-2a trial

Glenmark’s dermatitis molecule displays positive results in phase-2a trial.....»»

Category: featuresSource: livemintAug 1st, 2017

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma.....»»

Category: press-releasesSource: businesswireindiaJun 27th, 2017

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017.....»»

Category: press-releasesSource: businesswireindiaJun 5th, 2017

Boehringer Ingelheim to invest €65 million in avian vaccines

Boehringer Ingelheim to invest €65 million in avian vaccines.....»»

Category: press-releasesSource: businesswireindiaApr 18th, 2018

Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford to Investigate the Effects of Empagliflozin in People with Chronic Kidney Disease

Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford to Investigate the Effects of Empagliflozin in People with Chronic Kidney Disease.....»»

Category: press-releasesSource: businesswireindiaApr 18th, 2018

Biocon partner Mylan enters pact with Fujifilm to commercialise Humira biosimilar in Europe

Biocon partner Mylan enters pact with Fujifilm to commercialise Humira biosimilar in Europe.....»»

Category: topSource: moneycontrolApr 11th, 2018

HeartSciences Announces Publication of Clinical Study Results in the Journal of the American College of Cardiology (JACC)

HeartSciences Announces Publication of Clinical Study Results in the Journal of the American College of Cardiology (JACC).....»»

Category: press-releasesSource: businesswireindiaApr 10th, 2018

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors.....»»

Category: press-releasesSource: businesswireindiaApr 5th, 2018

Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis

Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis.....»»

Category: press-releasesSource: businesswireindiaMar 20th, 2018